✦ LIBER ✦

Monotherapy with GI262570, a non-thiazolidinedione PPARγ agonist, reduces triglyceride and increases HDL-C in patients with type 2 diabetes

✍ Scribed by F.T. Fiedorek; G.G. Wilson; M. Abou-Donia; L. Frith; J. Patel

Book ID: 117369694
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 98 KB
Volume: 50
Category: Article
ISSN: 0168-8227
DOI: 10.1016/s0168-8227(00)81595-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monotherapy with GI262570, a non-thiazol

Monotherapy with GI262570, a non-thiazolidinedione PPARγ agonist, improves glycemic control in type 2 diabetes mellitus patients (T2DM)

✍ F.T. Fiedorek; M. Abou-Donia; G.G. Wilson; L. Frith; J. Patel 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 98 KB

GI262570, a tyrosine-based PPARγ agonist

GI262570, a tyrosine-based PPARγ agonist, reduces triglycerides and increases HDL-C concentrations in patients with type 2 diabetes mellitus when combined with glibenclamide treatment

✍ Lata Kler; Robert C. Edwards; Simon J. McNeil; Patrick Round 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 207 KB

Ragaglitazar: The Pharmacokinetics, Phar

Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

✍ Skrumsager, B. K.; Nielsen, K. K.; Müller, M.; Pabst, G.; Drake, P. G.; Edsberg, 📂 Article 📅 2003 🏛 Sage Publications 🌐 English ⚖ 193 KB

Efficacy and safety of the PPARγ partial

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta

Administration of glutathione in patient

Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1

✍ Martina, V.; Bruno, G. A.; Zumpano, E.; Origlia, C.; Quaranta, L.; Pescarmona, G 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 96 KB